# US 12,691,171 B2 · Coronavirus vaccine formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,691,171 B2
- Document ID: US12691171B2
- Status: Granted
- Kind: B2
- Application number: 17/795,337
- Filed: 2021-01-27
- Published: 2023-03-09
- Granted: 2026-07-28
- Earliest claimed: 2020-01-27
- Applicants: Novavax, Inc.
- Inventors: Gale Smith; Michael J. Massare; Jing-Hui Tian
- Web page: https://patentgrep.com/patent/US12691171B2

## CPC

- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- C07K 2319/21: containing a His-tag
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

## Claims

### Claim 1

A coronavirus (CoV) Spike(S) glycoprotein comprising:
(i) an S1 subunit comprising an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7); wherein the S1 subunit comprises an N-terminal domain (NTD); a receptor binding domain (RBD), and subdomains 1 and 2 (SD1/2);
wherein the N-terminal domain comprises up to about 20 modifications compared to a NTD of a CoV S glycoprotein of SEQ ID NO: 2;
wherein the RBD comprises up to about 30 modifications compared to a RBD of a CoV S glycoprotein of SEQ ID NO: 2;
wherein the SD1/2 comprises up to about 15 modifications compared to a SD1/2 of a CoV S glycoprotein of SEQ ID NO: 2; and
(ii) an S2 subunit, wherein amino acids 973 and 974 are proline,
wherein the S2 subunit comprises up to 15 additional modifications compared to the S2 subunit of a CoV S glycoprotein of SEQ ID NO: 2;
wherein the amino acids of the CoV S glycoprotein are numbered with respect to the CoV S glycoprotein of SEQ ID NO: 2;
wherein each modification is a mutation, deletion, or addition of one amino acid.

### Claim 2 (depends on 1)

The CoV S glycoprotein of claim 1, wherein the NTD of the CoV S glycoprotein comprises between about 5 and about 10 modifications compared to the NTD of SEQ ID NO: 2.

### Claim 3 (depends on 1)

The CoV S glycoprotein of claim 1, wherein the NTD of the CoV S glycoprotein comprises between about 8 and about 12 modifications compared to the NTD of SEQ ID NO: 2.

### Claim 4 (depends on 1)

The CoV S glycoprotein of claim 1, wherein the RBD of the CoV S glycoprotein comprises between about 18 and about 23 modifications compared to the RBD of SEQ ID NO: 2.

### Claim 5 (depends on 1)

The CoV S glycoprotein of claim 1, wherein the RBD of the CoV S glycoprotein comprises between about 12 and about 17 modifications compared to the RBD of SEQ ID NO: 2.

### Claim 6 (depends on 1)

The CoV S glycoprotein of claim 1, wherein the RBD of the CoV S glycoprotein comprises between about 5 and about 10 modifications compared to the RBD of SEQ ID NO: 2.

### Claim 7 (depends on 1)

The CoV S glycoprotein of claim 1, wherein the RBD of the CoV S glycoprotein comprises between about 15 and about 20 modifications compared to the RBD of SEQ ID NO: 2.

### Claim 8 (depends on 1)

The CoV S glycoprotein of claim 1, wherein the SD1/2 of the CoV S glycoprotein comprises between about 3 and about 10 modifications compared to the SD1/2 of SEQ ID NO: 2.

### Claim 9 (depends on 1)

The CoV S glycoprotein of claim 1, wherein the S2 subunit of the CoV S glycoprotein comprises between about 3 and about 10 modifications compared to the S2 subunit of SEQ ID NO: 2.

### Claim 10 (depends on 1)

The CoV S glycoprotein of claim 1, wherein the CoV S glycoprotein comprises one or more modifications at a position selected from the group consisting of 56, 57, 131, 404, 488, 439, 471, 601, 642, and 668, wherein the CoV S glycoprotein is numbered according to SEQ ID NO: 2.

### Claim 11 (depends on 1)

A nanoparticle comprising the CoV S glycoprotein of claim 1 and a non-ionic detergent.

### Claim 12 (depends on 11)

The nanoparticle of claim 11, wherein the non-ionic detergent is selected from the group consisting of polysorbate-20 (PS20), polysorbate-40 (PS40), polysorbate-60 (PS60), polysorbate-65 (PS65), and polysorbate-80 (PS80).

### Claim 13 (depends on 11)

An immunogenic composition comprising the nanoparticle of claim 11 and a pharmaceutically acceptable buffer.

### Claim 14 (depends on 13)

The immunogenic composition of claim 13, comprising an adjuvant.

### Claim 15 (depends on 14)

The immunogenic composition of claim 14, wherein the adjuvant is a saponin adjuvant.

### Claim 16 (depends on 13)

The immunogenic composition of claim 13, wherein the saponin adjuvant comprises at least two iscom particles, wherein:
the first iscom particle comprises fraction A of Quillaja Saponaria Molina and not fraction C of Quillaja Saponaria Molina; and
the second iscom particle comprises fraction C of Quillaja Saponaria Molina and not fraction A of Quillaja Saponaria Molina.

### Claim 17 (depends on 16)

The immunogenic composition of claim 16, wherein fraction A of Quillaja Saponaria Molina accounts for 50-96% by weight and fraction C of Quillaja Saponaria Molina accounts for the remainder, respectively, of the sum of the weights of fraction A of Quillaja Saponaria Molina and fraction C of Quillaja Saponaria Molina in the adjuvant.

### Claim 18 (depends on 16)

The immunogenic composition of claim 16, wherein fraction A of Quillaja Saponaria Molina and fraction C of Quillaja Saponaria Molina account for about 85% by weight and about 15% by weight, respectively, of the sum of the weights of fraction A of Quillaja Saponaria Molina and fraction C of Quillaja Saponaria Molina in the adjuvant.

### Claim 19 (depends on 13)

The immunogenic composition of claim 13, comprising from about 3 μg to about 25 μg of CoV S glycoprotein.

### Claim 20 (depends on 13)

The immunogenic composition of claim 13, comprising about 5 μg of CoV S glycoprotein.

### Claim 21 (depends on 14)

The immunogenic composition of claim 14, comprising about 50 μg of adjuvant.

### Claim 22 (depends on 13)

A method of stimulating an immune response against SARS-COV-2 in a human comprising administering the immunogenic composition of claim 13.

### Claim 23 (depends on 22)

The method of claim 22, wherein the immunogenic composition comprises an adjuvant.

### Claim 24 (depends on 23)

The method of claim 23, wherein the adjuvant is a saponin adjuvant.

### Claim 25 (depends on 24)

The method of claim 24, wherein the saponin adjuvant comprises at least two iscom particles, wherein:
the first iscom particle comprises fraction A of Quillaja Saponaria Molina and not fraction C of Quillaja Saponaria Molina; and
the second iscom particle comprises fraction C of Quillaja Saponaria Molina and not fraction A of Quillaja Saponaria Molina.

### Claim 26 (depends on 25)

The method of claim 25, wherein fraction A of Quillaja Saponaria Molina accounts for 50-96% by weight and fraction C of Quillaja Saponaria Molina accounts for the remainder, respectively, of the sum of the weights of fraction A of Quillaja Saponaria Molina and fraction C of Quillaja Saponaria Molina in the adjuvant.

### Claim 27 (depends on 25)

The method of claim 25, wherein fraction A of Quillaja Saponaria Molina and fraction C of Quillaja Saponaria Molina account for about 85% by weight and about 15% by weight, respectively, of the sum of the weights of fraction A of Quillaja Saponaria Molina and fraction C of Quillaja Saponaria Molina in the adjuvant.

### Claim 28 (depends on 22)

The method of claim 22, comprising from about 3 μg to about 25 μg of CoV S glycoprotein.

### Claim 29 (depends on 22)

The method of claim 22, comprising about 5 μg of CoV S glycoprotein.

### Claim 30 (depends on 23)

The method of claim 23, comprising about 50 μg of adjuvant.
